Sep 2022

Building the data foundations to accelerate drug discovery

Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Jul 2022

Fueling continuous innovation at BenevolentAI

BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.
May 2022

FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval

The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
Feb 2022

Please don’t use this sentence out of context

BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of ​​co​​ntext in information extraction.